Official Title
Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities: Multicenter, Randomized, Open-labeled Controlled Trial
Brief Summary

No optimal antiviral intervention has been yet validated to treat COVID-19 disease. Comorbidities, such as older age, obesity, diabetes, history of cardiovascular diseases are associated with poor prognosis. This study aims to evaluate the efficacy of two experimental antiviral treatments, compared to standard of care (SOC), to prevent clinical worsening, hospitalization or death at day 14 in adults with documented SARS-CoV-2 infection, asymptomatic or with symptoms lasting less than 8 days, and associated comorbidities without any severity criteria of the disease at inclusion. Participants will be randomized to receive SOC alone or SOC + hydroxychloroquine 200 mg three times a day during 10 days or SOC + association of niclosamide 2 g at J1 then 500 mg two times a day with diltiazem 60 mg three times a day during 10 days. Efficacy and tolerance of each treatments will be compared across the three treatment groups during the 28 days of follow-up.

Not yet recruiting

Other: Standard of care (SOC)
SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen…) during the whole study duration
SOC + Diltiazem-Niclosamide
SOC + Hydroxychloroquine
standard of care (SOC)

Drug: Hydroxychloroquine
200 mg x 3 per day during 10 days in addition to SOC
SOC + Hydroxychloroquine

Drug: Association of diltiazem and niclosamide
niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC
SOC + Diltiazem-Niclosamide

Eligibility Criteria

Inclusion Criteria:

- Positive SARS-CoV-2 test on nasopharyngeal swab

- Onset of symptoms

Eligibility Gender
Eligibility Age
Minimum: 18 Years

Karine Faure, MD,PhD
0320445962 +33

Karine Faure, MD,PhD
Principal Investigator
University Hospital, Lille

University Hospital, Lille
I-site University Lille North Europe
NCT Number
MeSH Terms